RLMD

Relmada Therapeutics Inc

4.55

Aug 27 • 1:52 PM ET -0.01 (-0.11%)

Healthcare Biotechnology USA Small NASD

Peers: AXSM INCY KYMR BMRN CRNX NBIX RYTM VKTX KRYS MDGL

| Held by: VTI IWM VXF IWO XPH VTWO PSIL IWC VHT VFMO

Index	RUT
Market Cap	484.82M
Enterprise Value	267.09M
Income	-61.93M
Sales	0.00M
Book/sh	1.94
Cash/sh	2.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Jun 20, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.35
P/C	2.23
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	29.52
Current Ratio	29.52
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.93
EPS next Y	-0.78
EPS next Q	-0.14
EPS this Y	57.47%
EPS next Y	-25.95%
EPS next 5Y	16.55%
EPS past 3/5Y	35.03% 17.54%
Sales past 3/5Y	- -
EPS Y/Y TTM	57.98%
Sales Y/Y TTM	-
EPS Q/Q	61.35%
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	44.86% -

Insider Own	12.88%
Insider Trans	0.00%
Inst Own	85.01%
Inst Trans	17.70%
ROA	-51.57%
ROE	-55.66%
ROIC	-29.98%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.38%
SMA50	-18.42%
SMA200	-16.69%
Trades

Shs Outstand	106.67M
Shs Float	92.93M
Short Float	13.87%
Short Ratio	7.51
Short Interest	12.89M
52W High	8.00 -43.19%
52W Low	0.61 642.65%
Volatility	4.54% 5.62%
ATR (14)	0.27
RSI (14)	33.09
Beta	0.46
Rel Volume	0.15
Avg Volume	1.72M
Volume	173,540

Perf Week	-2.05%
Perf Month	-11.58%
Perf Quarter	-37.31%
Perf Half Y	-1.20%
Perf YTD	-5.90%
Perf Year	578.86%
Perf 3Y	39.42%
Perf 5Y	-81.21%
Perf 10Y	-14.95%
Recom	1.00
Target Price	12.67
Prev Close	4.55
Price	4.55
Change %	-0.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-26	Initiated	H.C. Wainwright	Buy	$12
Mar-24-26	Initiated	Piper Sandler	Overweight	$12
Jan-23-26	Resumed	Leerink Partners	Outperform	$8
Dec-22-25	Initiated	Jefferies	Buy	$69
Nov-19-25	Upgrade	Mizuho	Neutral → Outperform	$10
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral	$23 → $1
Sep-17-24	Upgrade	Jefferies	Hold → Buy	$3.50 → $13
Jun-05-24	Downgrade	Goldman	Neutral → Sell	$3 → $2
Oct-14-22	Downgrade	Truist	Buy → Hold	$90 → $10
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Goldman	Buy → Neutral	$81 → $8
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform	$64 → $7
Nov-18-21	Initiated	Mizuho	Buy	$50
May-20-21	Resumed	Goldman	Buy	$78
Oct-28-20	Downgrade	Goldman	Buy → Neutral	$69 → $40
Jul-14-20	Initiated	Oppenheimer	Outperform	$75
May-04-20	Initiated	SunTrust	Buy	$75
Apr-21-20	Initiated	Goldman	Buy	$63
Jan-27-20	Initiated	Jefferies	Buy	$75
Jan-10-20	Initiated	SVB Leerink	Outperform	$50

Show Previous Ratings

Aug-07-26 01:09AM	Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ... (GuruFocus.com) -8.01%
Aug-06-26 04:05PM	Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-26 08:30AM	Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer (GlobeNewswire)
Jul-16-26 07:05AM	Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 (GlobeNewswire) -12.08%
Jun-29-26 07:00AM	Relmada Therapeutics Joins Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
07:00AM	Loading…
Jun-11-26 07:00AM	Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program (GlobeNewswire)
May-28-26 07:00AM	Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-26 01:02AM	Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
May-12-26 04:05PM	Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-06-26 07:00AM	Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026 (GlobeNewswire) +6.94%
May-05-26 07:00AM	Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 (GlobeNewswire)
Mar-19-26 11:01PM	Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
08:14PM	Relmada Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
04:01PM	Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update (GlobeNewswire)
Mar-12-26 07:00AM	Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 (GlobeNewswire)
03:00AM	Loading…
03:00AM	BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director (TMX Newsfile)
Mar-09-26 07:00PM	50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today (24/7 Wall St.) +61.12% -7.67%
04:30PM	Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
08:48AM	Why Is Relmada Therapeutics Stock Soaring Monday? (Benzinga)
07:05AM	Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing (GlobeNewswire)
07:00AM	Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Feb-26-26 12:07PM	Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders (PR Newswire)
Jan-12-26 07:00AM	Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications (GlobeNewswire)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly)
Dec-03-25 07:30AM	Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology (GlobeNewswire)
Nov-20-25 10:15AM	This Stock Is Up 704% in 2025 But Has No Products to Its Name (Barchart)
Nov-14-25 12:02AM	Relmada Therapeutics Inc (RLMD) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-13-25 04:01PM	Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates (GlobeNewswire)
Nov-07-25 07:30AM	Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 (GlobeNewswire)
Nov-04-25 07:09AM	Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +25.91%
07:01AM	Loading…
07:01AM	Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer (GlobeNewswire)
Oct-07-25 07:30AM	Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 (GlobeNewswire)
Sep-23-25 07:24PM	Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data (Insider Monkey)
Sep-16-25 11:20AM	Sidoti Events, LLC's Virtual September Small-Cap Conference (ACCESSWIRE)
09:00AM	Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Sep-10-25 07:15AM	Relmada Issues Mid-Year CEO Letter to Shareholders (GlobeNewswire)
Sep-03-25 04:10PM	Exclusive: Relmada CEO says his recent buy reflects significant undervaluation (Investing.com) -6.80%
Sep-02-25 03:53AM	Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study (Insider Monkey) +26.79%
Aug-07-25 04:05PM	Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC (GlobeNewswire)
Jul-31-25 07:00AM	Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 (GlobeNewswire)
Jul-15-25 08:00AM	Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 (GlobeNewswire)
Jul-09-25 08:00AM	DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors (GlobeNewswire)
Jun-17-25 07:00AM	Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology (GlobeNewswire)
May-13-25 09:08AM	Q1 2025 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... (GuruFocus.com)
May-12-25 04:01PM	Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.05%
May-08-25 07:30AM	Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire) +5.64%
Apr-28-25 01:38PM	Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 (GlobeNewswire) -44.64%
Apr-27-25 09:00AM	UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
Apr-24-25 08:00AM	Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data (GlobeNewswire) +6.86%
Apr-14-25 08:41AM	UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
07:30AM	Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
Mar-28-25 07:05AM	Q4 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... (GuruFocus.com)
Mar-27-25 08:07PM	Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:05PM	Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (GlobeNewswire)
Mar-26-25 09:00AM	Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 (GlobeNewswire)
Mar-25-25 07:30AM	Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. (GlobeNewswire) +6.09%
Feb-07-25 06:46AM	Relmada acquires Tourettes therapy rights from Asarina (Pharmaceutical Technology) -9.62%
Feb-06-25 07:30AM	Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB (GlobeNewswire) -10.00%
Dec-09-24 07:30AM	Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 (GlobeNewswire) +5.14%
Dec-05-24 07:36AM	Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile (TipRanks) -28.57%
Dec-04-24 07:30AM	Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance (GlobeNewswire) -77.26%
Nov-19-24 09:00AM	Relmada Therapeutics to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-14-24 07:30AM	Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease (GlobeNewswire)
Nov-10-24 09:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024 (Market Exclusive)
Nov-08-24 02:28AM	Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Nov-07-24 04:32PM	Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-04-24 04:30PM	Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Sep-12-24 01:07AM	Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD) (GuruFocus.com) +8.28%
01:06AM	Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares (GuruFocus.com)
Aug-12-24 09:35AM	Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-08-24 01:51PM	Q2 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -29.01%
Aug-07-24 04:05PM	Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Aug-05-24 07:30AM	Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire) -5.83%
Jun-18-24 08:30AM	Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry (PR Newswire)
Jun-10-24 07:30AM	Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire) +5.76%
Jun-03-24 07:30AM	Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-11-24 08:41AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:20AM	Q1 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:40AM	Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 09:55PM	RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (PR Newswire)
May-06-24 07:30AM	Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 (PR Newswire)
Mar-20-24 10:27AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript (Insider Monkey) -17.41%
06:27AM	Q4 2023 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:52PM	RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
05:31PM	Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results (GuruFocus.com)
04:15PM	Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results (PR Newswire)
Mar-12-24 07:30AM	Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 (PR Newswire)
Mar-05-24 07:30AM	Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (PR Newswire)
Feb-01-24 03:02PM	Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares (GuruFocus.com) +16.03%
Jan-05-24 05:12PM	Health Care Roundup: Market Talk (The Wall Street Journal) +7.27%
Jan-04-24 07:30AM	Relmada Therapeutics Provides Corporate Update (PR Newswire) -31.68%
Dec-29-23 08:47AM	11 Best Psychedelic Stocks to Buy in 2024 (Insider Monkey) +9.23%
Dec-20-23 02:39PM	5 Most Promising Psychedelic Stocks According to Hedge Funds (ready to review) (Insider Monkey)
02:14PM	5 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey)
Nov-10-23 01:57PM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 06:47PM	Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial Results (GuruFocus.com)

Relmada Therapeutics, Inc. engages in the development of clinical-stage drugs. The firm's pipeline includes NDV-01 and Sepranolone. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Pharm.D.Dr. Sergio Traversa M.B.A.

R.Ph.Mr. Maged S. Shenouda M.B.A.

COO & DirectorMr. Paul E. Kelly M.B.A.

M.B.A.Mr. Charles S. Ence CPA

VP & Head of Clinical OperationsMs. Gina DiGuglielmo

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TRAVERSA SERGIO	Chief Executive Officer	Dec 15 '25	Buy	4.12	27,500	113,300	1,300,000	Dec 16 09:30 AM
Shenouda Maged	Chief Financial Officer	Dec 15 '25	Buy	4.12	11,665	48,060	800,000	Dec 16 09:30 AM
Shenouda Maged	Chief Financial Officer	Nov 05 '25	Buy	2.20	500,000	1,100,000	788,335	Nov 06 07:30 AM
Ence Chuck	CAO and COO	Nov 05 '25	Buy	2.20	136,000	299,200	403,931	Nov 06 07:30 AM
TRAVERSA SERGIO	Chief Executive Officer	Nov 05 '25	Buy	2.20	272,500	599,500	1,272,500	Nov 06 07:30 AM
Kelly Paul Edward	Chief Operating Officer	Nov 05 '25	Buy	2.20	90,000	198,000	502,295	Nov 06 07:30 AM
TRAVERSA SERGIO	Chief Executive Officer	Aug 28 '25	Buy	0.74	55,976	41,422	1,000,000	Aug 28 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RLMD

Relmada Therapeutics Inc

Upgrade your Finviz experience